Allarity Therapeutics, Inc. Common Stock

ALLRNASDAQUSD
1.19 USD
0.02 (1.71%)AT CLOSE (11:59 AM EDT)
1.16
0.03 (2.52%)
POST MARKET (AS OF 05:46 PM EDT)
Post Market
AS OF 05:46 PM EDT
1.16
0.03 (2.52%)
🔴Market: CLOSED

Shares of Allarity Therapeutics, Inc. Common Stock (ALLR) are trading at $1.19. Our models show a "Neutral" technical signal alongside a "Sell" fundamental rating. This is driven by a concerning Altman Z-Score in the distress zone, a weak Piotroski F-Score of 0/9, negative Return on Equity and a bullish Golden Cross on the moving averages. On valuation, ALLR trades roughly in line with sector averages — neither particularly cheap nor expensive.

Technical & fundamental data as of Jul 17, 2026.

Open?$1.17
High?$1.23
Low?$1.15
Prev. Close?$1.17
Volume?82.9K
Avg. Volume?149.9K
VWAP?$1.18
Rel. Volume?0.55x
Bid / Ask
Bid?$1.15 × 1.0K
Ask?$1.22 × 100
Spread?$0.07
Midpoint?$1.19
Valuation & Ratios
Market Cap?18.9M
Shares Out?15.9M
Float?15.8M
Float %?99.8%
P/E Ratio?N/A
P/B Ratio?2.74
EPS?-$0.71
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
Allarity Therapeutics Inc is a clinical-stage, precision medicine pharmaceutical company focused on developing novel anti-cancer therapeutics for patients with high unmet medical needs. The company is actively advancing the development of stenoparib, an orally available, small-molecule inhibitor for patients with advanced recurrent ovarian cancer. It is leveraging its proprietary Drug Response Predictor (DRP) technology to refine patient selection and improve clinical outcomes. The company operates as a single operating and reporting segment (developing a treatment for ovarian cancer) in two geographic areas: Denmark and the United States. It is focused on the clinical development of its lead program: Stenoparib, which is being co-developed with a drug specific DRP companion diagnostic.
Employees
8
Market Cap
18.6M
Industry
PHARMACEUTICAL PREPARATIONS
Listed
2021-12-21
Address
24 SCHOOL ST., 2ND FLOOR
BOSTON, MA 02108
Phone: 401-426-4664
Technical OutlookNeutral
Strong SellNeutralStrong Buy
Long-Term (Tide)? Bearish(-1/3)
Medium-Term (Wave)? Neutral(0/3)
Short-Term (Ripple)? Bullish(+2/3)
MA Alignment?Mixed
Full Technical Analysis →
Fundamental OutlookSell
Strong SellNeutralStrong Buy
F-Score?
3
Z-Score?
0
Momentum?
50
Short Sent.?
80
Piotroski F-Score?0/9Weak
Altman Z-Score?-6.19Distress
Confidence?40%Low
Full Fundamental Analysis →
Short InterestLow
Short % of Float?0.51%Low
Short Interest?80.8K
Days to Cover?1.0
Free Float15.8M
Avg Daily Volume145.0K
Settlement Date2026-06-30
Financial Health
Current Ratio?0.88Weak
Quick Ratio?0.88Weak
Cash Ratio?0.71Adequate
Debt/Equity?3.11High
ValuationFAIRLY VALUEDvs 1 peers + S&P 500
Score
67/100
P/E?
N/A
P/B?
Peers
100
S&P
60
2.74CHEAP
P/S?
Peers
100
S&P
3
54.88HIGH
P/FCF?
N/A
EV/EBITDA?
S&P
97
-1.7CHEAP
EV/Sales?
Peers
100
S&P
3
59.76HIGH
Returns & Efficiency
ROE?
S&P
3
-162.6%WEAK
ROA?
S&P
3
-32.2%WEAK
Cash Flow & Enterprise
FCF?$-16699000
Enterprise Value?$20.6M
Fundamentals ratios updated end of day